Introduction
Bemfola® (Finox AG, Switzerland), biosimilar follitropin alfa, is a biological medicinal product similar to the originator Gonal-f® (Merck Serono, Germany). Clinical efficacy was demonstrated in an assessor-blinded, randomized, parallel-group, multi-centre, phase III study conducted in women undergoing assisted reproduction techniques on 15 centres in six European countries.
(1) Clinical equivalence of Bemfola® to the reference product Gonal-f® was demonstrated in terms of number of oocytes retrieved during stimulation of multi-follicular development in patients undergoing superovulation for assisted reproductive technology (ART). The percentages of patients with a clinical and ongoing pregnancy and live born children was higher in the Gonal-f® group compared with the Bemfola® group for treatment cycle 1, even if it was not statistically significant. In contrast to data from treatment cycle 1, the clinical and ongoing pregnancy rate for Bemfola® and Gonal-f® evaluated from treatment cycle 2 was higher in the Bemfola® group compared with the Gonal-f® group, although not significant. One of the most important adverse events of gonadotropins is ovarian hyper stimulation syndrome (OHSS), reported by more patients in the Bemfola® group in comparison to the Gonal-f® group, 5.6% vs 3.3%, respectively. The majority of these events were mild to moderate.
Objectives
Whether the lower cost of the biosimilar does provide an improvement in cost-effectiveness has not yet been demonstrated for Bemfola®. The aim of this project was to perform a cost-effectiveness analysis (CEA) comparing costs and efficacy/ safety of the two comparators (Bemfola® vs Gonal-f ®) in an Italian contest.
Methods

Results
The results of the CEA are shown in Table C . The total cost is of 3,483 Euro for Bemfola® and 3,550 Euro for Gonal-f®. The efficacy, i.e. live birth rate, associated with Gonal-f® was 0.52, whereas it was 0.47 for Bemfola®. In other words, there will be 52 live-born children for 100 patients treated with the originator and 47 live-born children per 100 patients treated with the biosimilar. The average cost per live-birth was estimated to be €6,787 in the case of the originator and €7,449 in the case of the biosimilar, underlying the lower cost per live-birth for Gonal-f®. Furthermore, Gonal-f® generated an ICER equal to €1,210 compared to Bemfola®, which is the additional cost required for Gonal-f® to gain an additional live-birth in comparison with Bemfola®.
Conclusions
The results of this cost-effectiveness analysis indicate that Gonal-f® is a cost-efficient treatment strategy for the Italian health service compared to Bemfola® in the treatment of infertility. Actually, Gonal-f® provides a lower average cost per live-birth in comparison with Bemfola® (€6,787 for Gonal-f® vs €7,449 for Bemfola®), whereas the incremental cost per live-birth resulted in €1,210. The reliability of costeffectiveness research can be greatly improved in time as data continues to grow and long-term data are generated correlating to efficacy in the individual patient populations of interest.
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Table B -Model input data: Health costs
Clinical evidence
The clinical evidence on which the economic analysis was based was retrieved from a single study conducted by Rettenbacher et al. (1) , since other publications that compare Bemfola® with Gonal-f® are not available. This multi-centre phase III study (1) compared efficacy and safety of follitropin alfa biosimilar (Bemfola®) versus follitropin alfa originator (Gonal-f®) in 333 women undergoing ovarian stimulation for in vitro fertilization (IVF) to reach the superovulation needed for ART. Clinical data on number of subjects, total dose of gonadotropins, pregnancies and liveborn children, OHSS for both first and second cycle of the study by Rettenbacher et al. were used to feed the model and are represented in table A. 220 patients in the Bemfola® group and 113 in the Gonal-f® group were assessed in the first cycle of treatment with a mean total dose of r-hFSH of 1555.7 (±293.0) IU for Bemfola® and 1569.2 (±259.20) IU for Gonal-f®. At cycle 1, clinical pregnancy rate per embryo transfer was 40.2% for Bemfola® and 48.2% for Gonal-f®, whereas patients with liveborn children were 80 (35.7%) for Bemfola® and 50 (43.9%) for Gonal-f®. At second treatment cycle, 72 patients in the Bemfola ® group and 38 in the Gonal-f ® were treated with a mean total dose of r-hFSH of 1612.3 (±217.7) IU for Bemfola® and 1604.9 (±216.61) IU for Gonal-f®. Clinical pregnancy rate at cycle was 38.5% for Bemfola® and 27.8% for Gonal-f® and ongoing pregnancy rate was 33.8% for Bemfola® and 25% for Gonal-f®. OHSS was assessed only for the first cycle of treatment and occurred in 14 (5.6%) of the Bemfola® patients vs 4 (3.3%) of the Gonal-f® patients. The majority of OHSS (4.8% and 2.5% for Bemfola® and Gonald-f®, respectively) were mild to moderate.
Costs
The perspective of this economic evaluation was the one of the Italian National Health Service (NHS). All costs are expressed in Euros and are represented in (2) Regarding OHSS, two different tariffs were applied based on OHSS severity and, specifically, mild/moderate OHSS included gynaecological visits and laboratory tests for an amount of around 160 €, whereas severe OHSS entailed an hospitalization (DRG 369) with a tariff of around 800 €.
Model design
CEA is a method of assessing health gains in relation to the costs of different health interventions. A cost-effectiveness model was developed to assess the clinical and economical outcomes of the Bemfola® and Gonal-f® treatments in Italy. In order to feed the model all costs described in the cost section were applied to the clinical data from the study by Rettenbacher et al. (1) . Total costs of Bemfola® and Gonal-f® arms were obtained by the sum of all costs derived from both the first and second cycle of treatment and were divided by the efficacy parameter, represented by live birth rates, in order to obtain average costs per live birth. Incremental cost-effectiveness ratio (ICER) was calculated as the difference in costs divided by the difference in efficacy of the two treatment arms. 
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